Charles River to acquire CDMO Vigene Biosciences for $292.5m
Charles River Laboratories signs a definitive agreement to acquire US-based gene therapy CDMO, Vigene Biosciences, for $292.5m.
News
US Supreme Court rejects Sandoz’s plea over biosimilar Erelzi
The US Supreme Court rejects Sandoz’s appeal to review Federal Circuit’s 2020 ruling on its biosimilar...
Appili to progress Phase III oral Covid-19 treatment trial
Appili Therapeutics to continue Phase III Covid-19 trial of oral therapy, Avigan/Reeqonus, without modification.
Natco Pharma and Lilly sign licencing deal for baricitinib use in India
Natco Pharma signs licencing agreement with Eli Lilly for baricitinib to treat Covid-19 in India.
PharmaEssentia resubmits BLA for polycythemia vera therapeutic
PharmaEssentia USA resubmits BLA to the FDA, seeking approval for ropeginterferon alfa-2b-njft for polycythemia vera treatment.
Dr Reddy’s starts launch of Sputnik V Covid-19 vaccine in India
Dr Reddy’s Laboratories has started inoculation with Russia’s Covid-19 vaccine, Sputnik V, as part of the soft launch in India after it obtained regulatory clearance from the Central Drugs Laboratory.…
Poll finds independent verification of ESG disclosures to be important
Verification by independent auditors ensures that a company’s financial and non-financial data is accurate. It helps in filling the gap between ESG disclosures and building investor trust. Verdict has conducted…
UK NICE rejects NHS use of ozanimod for MS treatment
The UK National Institute for Health and Care Excellence (NICE) has decided not to recommend ozanimod for the treatment of relapsing multiple sclerosis (MS) patients on National Health Service (NHS)…
CD&R to acquire UDG Healthcare for $3.7bn
Private equity firm Clayton, Dubilier & Rice (CD&R) has agreed to acquire Ireland-based UDG Healthcare for a total of $3.7bn (£2.6bn) in cash. According to the deal, UDG will receive…
Accountability of environmental, social, and governance (ESG) issues should lie with senior executives: Poll
The success of a business is no longer being measured based on financial performance alone. In a poll Verdict has conducted to assess how important it is for the ultimate…
Algernon’s Ifenprodil lowers interleukin 6 in Phase IIb/III Covid-19 trial
Algernon Pharmaceuticals has reported that NP-120 (Ifenprodil) statistical significantly lowered interleukin 6 (IL-6) in its Phase IIb/III trial to treat Covid-19. The change in IL-6 levels was one of the…
